These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 27607592)

  • 1. Cancer therapies in HIV cure research.
    Rasmussen TA; Anderson JL; Wightman F; Lewin SR
    Curr Opin HIV AIDS; 2017 Jan; 12(1):96-104. PubMed ID: 27607592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Interventions in HIV Cure Research.
    Rasmussen TA; Søgaard OS
    Adv Exp Med Biol; 2018; 1075():285-318. PubMed ID: 30030798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological strategies to target HIV persistence.
    Martrus G; Altfeld M
    Curr Opin HIV AIDS; 2016 Jul; 11(4):402-8. PubMed ID: 27054281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?
    Rasmussen TA; Lewin SR
    Curr Opin HIV AIDS; 2016 Jul; 11(4):394-401. PubMed ID: 26974532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eradication of HIV: current challenges and new directions.
    Marsden MD; Zack JA
    J Antimicrob Chemother; 2009 Jan; 63(1):7-10. PubMed ID: 18984648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current views on HIV-1 latency, persistence, and cure.
    Melkova Z; Shankaran P; Madlenakova M; Bodor J
    Folia Microbiol (Praha); 2017 Jan; 62(1):73-87. PubMed ID: 27709447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of Latency as Part of a Cure for HIV-1.
    Rasmussen TA; Tolstrup M; Søgaard OS
    Trends Microbiol; 2016 Feb; 24(2):90-97. PubMed ID: 26690612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
    Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
    Pierson T; McArthur J; Siliciano RF
    Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.
    Sung JA; Pickeral J; Liu L; Stanfield-Oakley SA; Lam CY; Garrido C; Pollara J; LaBranche C; Bonsignori M; Moody MA; Yang Y; Parks R; Archin N; Allard B; Kirchherr J; Kuruc JD; Gay CL; Cohen MS; Ochsenbauer C; Soderberg K; Liao HX; Montefiori D; Moore P; Johnson S; Koenig S; Haynes BF; Nordstrom JL; Margolis DM; Ferrari G
    J Clin Invest; 2015 Nov; 125(11):4077-90. PubMed ID: 26413868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.
    Laird GM; Bullen CK; Rosenbloom DI; Martin AR; Hill AL; Durand CM; Siliciano JD; Siliciano RF
    J Clin Invest; 2015 May; 125(5):1901-12. PubMed ID: 25822022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving Paradigms in HIV Malignancies: Review of Ongoing Clinical Trials.
    Bender Ignacio RA; Lin LL; Rajdev L; Chiao E
    J Natl Compr Canc Netw; 2018 Aug; 16(8):1018-1026. PubMed ID: 30099376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDAC inhibitors in HIV.
    Wightman F; Ellenberg P; Churchill M; Lewin SR
    Immunol Cell Biol; 2012 Jan; 90(1):47-54. PubMed ID: 22083528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kill: boosting HIV-specific immune responses.
    Trautmann L
    Curr Opin HIV AIDS; 2016 Jul; 11(4):409-16. PubMed ID: 27054280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Didehydro-Cortistatin A: a new player in HIV-therapy?
    Mousseau G; Valente ST
    Expert Rev Anti Infect Ther; 2016; 14(2):145-8. PubMed ID: 26581953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 1998 Oct; 47(RR-20):1-58. PubMed ID: 9809743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards an HIV cure: science and debate from the International AIDS Society 2013 symposium.
    Purcell DF; Elliott JH; Ross AL; Frater J
    Retrovirology; 2013 Nov; 10():134. PubMed ID: 24224983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV Provirus Stably Reproduces Parental Latent and Induced Transcription Phenotypes Regardless of the Chromosomal Integration Site.
    Hashemi FB; Barreto K; Bernhard W; Hashemi P; Lomness A; Sadowski I
    J Virol; 2016 Jun; 90(11):5302-14. PubMed ID: 26984732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.